Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on February 24, 2017. The filing discloses the approval of equity bonus awards and annual base salaries for executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
| Executive Officer | Position | FY 2017 Base Salary | Stock Options Granted | Bonus RSUs Granted | Change in Control RSUs |
|---|---|---|---|---|---|
| Phillip P. Chan, MD, PhD | President and CEO | $378,000 | 112,000 | 40,625 | 18,700 |
| Vincent J. Capponi | Chief Operating Officer | $314,000 | 105,000 | 35,938 | 17,900 |
| Kathleen P. Bloch | Chief Financial Officer | $275,000 | 89,000 | 32,813 | 15,700 |
| Robert H. Bartlett, MD | Chief Medical Officer | $0 (Consulting Fee: $54,000) | 20,000 | 0 | 0 |
Option Details: All options have a strike price of $5.60 and a 10-year term.
Material Changes Versus Prior Period
- Base Salary Increases: Effective January 1, 2017, base salaries increased for the CEO (approx. 8%), COO (approx. 7.9%), and CFO (approx. 7.8%).
- Compensation Structure: Dr. Bartlett's compensation remains unchanged from 2016, consisting of annual consulting fees.
- Equity Awards: New stock options and restricted stock units (RSUs) were granted on February 24, 2017, subject to specific performance milestones and vesting schedules.
Guidance, Outlook, Risks, and Unusual Items
Performance Milestones for Stock Options: Vesting is contingent upon achieving specific 2017 goals determined by the Board:
- 30% upon achieving budgeted revenues without exceeding budgeted operating expenses.
- 30% upon achieving multiple clinical trial and data objectives.
- 25% upon meeting financing goals.
- 15% upon achieving new or expanded major strategic partnerships.
Plan Authorization Risk: The filing states that the authorized Common Stock available under the 2014 Long-Term Incentive Plan is currently insufficient to cover all 2017 annual grants. The Company anticipates amending the Plan to increase authorized shares, subject to stockholder approval at the 2017 Annual Meeting.
Change in Control Provisions: Certain RSUs vest upon a "Change in Control" but are not considered outstanding unless approved by stockholders prior to such an event.
Important Facts for Investor Verification
- Verify the outcome of the stockholder vote at the 2017 Annual Meeting regarding the amendment to increase authorized shares under the Long-Term Incentive Plan.
- Monitor the achievement of the specific 2017 performance milestones (revenue, clinical trials, financing, partnerships) required for stock option vesting.
- Confirm the sufficiency of the company's cash reserves to fund the increased base salaries and potential cash bonuses.
- Review the definition of "Change in Control" in the 2014 Long-Term Incentive Plan to understand the implications for the specific RSU awards.